Atorvastatin for the prevention of coronary heart disease endpoints in patients with NIDDM (ASPEN)

Trial Profile

Atorvastatin for the prevention of coronary heart disease endpoints in patients with NIDDM (ASPEN)

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2010

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms ASPEN
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top